Showing the latest 10 filings. Sign in to filter or browse the full history.
Showing 10 of 37 filings.
14 Oct 20261 filing
Meeting Details
- Board meeting on 30 October 2026; time and venue not disclosed.
Key Agenda Items
- Consider unaudited standalone financial results for Q2 and H1 2026.
- Consider unaudited consolidated financial results for Q2 and H1 2026.
- Approval of Limited Review Report by Statutory Auditor.
12 Aug 20261 filing
No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
11 Aug 20262 filings
AGM Details
- AGM date and mode: 10 August 2026, VC/OAVM.
- Start time 12:30 PM; end time 01:05 PM.
- Record date: 03 August 2026; on-record shareholders: 29,814.
- Total resolutions passed: 5.
Resolutions and outcomes
- Resolution 1(a): Adoption of Audited Financial Statements; ordinary; passed.
- Resolution 1(b): Adoption of Audited Consolidated Financial Statements; ordinary; passed.
- Resolution 2: Re-appointment of Shashil Philip Mendosa (DIN 09667654); ordinary; passed.
- Resolution 3: Ratification of remuneration of Cost Auditor for FY 2025-26; ordinary; passed.
- Resolution 4: Ratification of remuneration of Cost Auditor for FY 2026-27; ordinary; passed.
- Resolution 5: Approval of Related Party Transactions for FY 2026-27 with IPCA Laboratories; ordinary; passed.
Voting observations
- All resolutions passed; majority in favour across the board.
- Interested directors and relatives abstained from RPT voting.
Q1 FY27 results and revision
- Revised press release for Q1 FY27 unaudited results; corrections to figures; submitted Aug 11, 2026.
- Standalone revenue from operations: 4,230.94 Lacs; up 45.01% YoY.
- Consolidated revenue from operations: 4,230.94 Lacs; up 28.11% YoY.
- Domestic revenue: 2,652.11 Lacs (Branded Formulation 737.67; Veterinary 587.35; P2P 1,327.09).
- Export revenue: 1,483.42 Lacs; up 68.03%.
- Standalone EBITDA margin: 11.84%; Consolidated EBITDA margin: 11.74%.
- Standalone net profit after tax: 210.03 Lacs; up 159.06%.
- Consolidated net profit after tax: 204.66 Lacs; up 105.44%.
- Other income: standalone 41.85 Lacs; down 45.89%.
10 Aug 20263 filings
AGM Details
- 47th AGM held on 10 August 2026 at 12:30 PM via VC/OAVM.
- 66 members attended; quorum satisfied.
- Results pending; combined voting results to be announced later.
Resolutions Put to Vote
- Adoption of Audited Financial Statements (including consolidated) for FY2025-26.
- Appointment of Director retiring by rotation.
- Ratification of Cost Auditor remuneration for FY2025-26.
- Ratification of Cost Auditor remuneration for FY2026-27.
- Approval of material related party transactions with IPCA Laboratories for 2026-27.
Voting Results
- Voting results pending; combined results to be announced within timeline.
Directors & Auditors
- No director changes announced at the AGM.
- Statutory Auditors attended; Cost Auditor remuneration ratified for FY2025-26 and FY2026-27.
Q1 FY27 results overview
- Unaudited Q1 FY27 results for Lyka Labs: standalone and consolidated financials for quarter ended 30 June 2026.
- Standalone Net Total Income rose 42.67% to Rs 4272.79 Lacs.
- Consolidated Net Total Income rose 26.95% to Rs 4272.79 Lacs.
- Domestic Revenue up 15.91% to Rs 2652.11 Lacs.
- Export Revenue up 68.03% to Rs 1483.42 Lacs.
- Standalone EBITDA margin 11.84% vs 14.16% in Q1 FY26.
- Consolidated EBITDA margin 11.74% vs 13.07% in Q1 FY26.
- Standalone Net Profit up 159.04% to Rs 210.01 Lacs.
- Consolidated Net Profit up 105.44% to Rs 204.66 Lacs.
- Board approved Q1 FY27 unaudited results at the August 10, 2026 meeting.
Financial results approved
- Unaudited standalone and consolidated Q1 2026 results approved by Board; Limited Review Report enclosed.
Divestment of Lyka BDR International Limited
- Board approved divestment of 100% equity in Lyka BDR International Limited; Audit Committee to implement.
NCLT merger sanction and restatement
- NCLT sanctioned merger of Lyka Export Limited with Lyka Labs Limited; restatement per IND AS 103.
Auditors' conclusions
- Statutory auditors express unqualified conclusion on both standalone and consolidated unaudited results.
Subsidiary disclosures
- Annexure notes Lyka BDR turnover 8% of consolidated income; net worth negative.
20 Jul 20261 filing
No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
17 Jul 20262 filings
AGM Details & Voting
- AGM date/time: 10 August 2026 at 12:30 p.m., via VC/OAVM.
- Remote e-voting window: 6 August 2026, 9:00 a.m. to 9 August 2026, 5:00 p.m.
- Cut-off date for voting rights: 3 August 2026.
- Notice and Annual Report sent electronically; physical copies dispensed per MCA/SEBI rules.
- Annual Report also available on the company's website.
- Shareholders may request electronic copy by emailing the Company Secretary.
Key updates
- 47th AGM on 10 August 2026 at 12:30 PM IST via VC/OAVM.
- Annual Report for FY 2025-26 available on Lyka Labs website.
- Letter sent to shareholders without registered emails with access link; cut-off for email registration: 10 July 2026.
- Reminder to update KYC per SEBI circular; required fields include PAN, address, mobile, bank details, and nomination.
- SEBI mandates electronic payments to physical folios lacking updated details from 1 April 2024.
- Queries via investor.helpdesk@in.mpms.mufg.com; service requests via MUFG portal.